Gender Differences Among Persons Entering Medication Treatment for Opioid Use Disorder in the Community

Overview

Journal Am J Addict

Specialty Psychiatry

Date 2022 Jun 2

PMID 35652902

Authors

Angela Di Paola

Noor Taweh

Breanne E Biondi

Ariadna Forray

Cynthia A Frank

Albert Shaw

Sandra A Springer

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: We evaluated gender differences among persons initiating medications for opioid use disorder (MOUD).

Methods: Analyses of baseline assessments for a study evaluating the impact of MOUD on outcomes included: demographics, DSM-5 diagnoses, depression severity, quality of life (QoL), and medication history (N = 125).

Results: When compared to men, women had a greater prevalence of generalized anxiety and posttraumatic stress disorders; and worse psychological QoL. Women were less likely to be prescribed psychiatric medications.

Discussion And Conclusions: Women may benefit from tailored multidisciplinary programs with MOUD.

Scientific Significance: This study identified that women with OUD seeking MOUD in the community had greater sedative hypnotic nonprescribed medication use and psychiatric comorbidity than men, all of which can contribute to poorer retention on MOUD and higher risk of morbidity and mortality. Thus, concurrent psychiatric disorder screening and treatment integrated with MOUD may improve retention on MOUD, opioid relapse and overdose for women.

Citing Articles

Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder.

Paschen-Wolff M, Greenfield S, McHugh R, Burlew K, Pavlicova M, Choo T Am J Addict. 2023; 32(6):584-592.

PMID: 37583120 PMC: 10841329. DOI: 10.1111/ajad.13463.

References

Arfken C, Klein C, di Menza S, Schuster C . Gender differences in problem severity at assessment and treatment retention. J Subst Abuse Treat. 2001; 20(1):53-7. DOI: 10.1016/s0740-5472(00)00155-0. View

Cleveland L, McGlothen-Bell K, Scott L, Recto P . A life-course theory exploration of opioid-related maternal mortality in the United States. Addiction. 2020; 115(11):2079-2088. PMC: 7587012. DOI: 10.1111/add.15054. View

McHugh R, Votaw V, Sugarman D, Greenfield S . Sex and gender differences in substance use disorders. Clin Psychol Rev. 2017; 66:12-23. PMC: 5945349. DOI: 10.1016/j.cpr.2017.10.012. View

Kosten T, Rounsaville B, KLEBER H . Ethnic and gender differences among opiate addicts. Int J Addict. 1985; 20(8):1143-62. DOI: 10.3109/10826088509056356. View

Serdarevic M, Striley C, Cottler L . Sex differences in prescription opioid use. Curr Opin Psychiatry. 2017; 30(4):238-246. PMC: 5675036. DOI: 10.1097/YCO.0000000000000337. View

Smid M, Stone N, Baksh L, Debbink M, Einerson B, Varner M . Pregnancy-Associated Death in Utah: Contribution of Drug-Induced Deaths. Obstet Gynecol. 2019; 133(6):1131-1140. PMC: 6548332. DOI: 10.1097/AOG.0000000000003279. View

Springer S, Biondi B, Frank C, El-Bassel N . A Call to Action to Combat the Opioid Epidemic Among Women. J Addict Med. 2020; 14(5):364-366. PMC: 7392801. DOI: 10.1097/ADM.0000000000000622. View

Ma J, Bao Y, Wang R, Su M, Liu M, Li J . Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018; 24(12):1868-1883. DOI: 10.1038/s41380-018-0094-5. View

Lee S, Humphreys K, Flory K, Liu R, Glass K . Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011; 31(3):328-41. PMC: 3180912. DOI: 10.1016/j.cpr.2011.01.006. View

10.

. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction. 2002; 97(9):1183-94. DOI: 10.1046/j.1360-0443.2002.00185.x. View

11.

Campbell A, Barbosa-Leiker C, Hatch-Maillette M, Mennenga S, Pavlicova M, Scodes J . Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. Am J Addict. 2018; 27(6):465-470. PMC: 6124662. DOI: 10.1111/ajad.12784. View

12.

Mazure C, Fiellin D . Women and opioids: something different is happening here. Lancet. 2018; 392(10141):9-11. DOI: 10.1016/S0140-6736(18)31203-0. View

13.

Brugal M, Domingo-Salvany A, Puig R, Barrio G, Garcia de Olalla P, de la Fuente L . Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction. 2005; 100(7):981-9. DOI: 10.1111/j.1360-0443.2005.01089.x. View

14.

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

15.

Stoltman J, Woodcock E, Lister J, Greenwald M, Lundahl L . Exploration of the telescoping effect among not-in-treatment, intensive heroin-using research volunteers. Drug Alcohol Depend. 2015; 148:217-20. PMC: 5535755. DOI: 10.1016/j.drugalcdep.2015.01.010. View

16.

Tanum L, Solli K, Latif Z, Saltyte Benth J, Opheim A, Sharma-Haase K . Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry. 2017; 74(12):1197-1205. PMC: 6583381. DOI: 10.1001/jamapsychiatry.2017.3206. View

17.

DeMaria Jr P, Sterling R, Weinstein S . The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment. Am J Addict. 2000; 9(2):145-53. DOI: 10.1080/10550490050173217. View

18.

Biondi B, Mohanty S, Vander Wyk B, Montgomery R, Shaw A, Springer S . Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemp Clin Trials Commun. 2021; 21:100704. PMC: 7807244. DOI: 10.1016/j.conctc.2021.100704. View

19.

Chan G, Stajic M, Marker E, Hoffman R, Nelson L . Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: analysis of medical examiner data. Acad Emerg Med. 2006; 13(5):543-7. DOI: 10.1197/j.aem.2005.12.011. View

20.

Huhn A, Dunn K . Challenges for Women Entering Treatment for Opioid Use Disorder. Curr Psychiatry Rep. 2020; 22(12):76. DOI: 10.1007/s11920-020-01201-z. View